<?xml version="1.0" encoding="UTF-8"?>

<trials>
    <trial>
        <main>
            <trial_id>RBR-294d68</trial_id>
            <utrn></utrn> 
            <reg_name>RBR-294d68</reg_name>
            <date_registration>03/12/2010</date_registration>
            <primary_sponsor>Bireme</primary_sponsor>
            <public_title>This record is just for testing</public_title>
            <acronym>ERAPT</acronym>
            <scientific_title>This record is just for testing</scientific_title>
            <scientific_acronym>ERAPT</scientific_acronym>
            <date_enrolment>01/08/2011</date_enrolment>
            <type_enrolment>anticipated</type_enrolment>
            <target_size>500</target_size>
            <recruitment_status>not yet recruiting</recruitment_status>
            <url>http://ec.teste.bvsalud.orghttp://localhost:8000/rg/RBR-294d68/</url>
            <study_type></study_type>
            <study_design>Double-Blind, randomized placebo control safety and efficacy study with single Group Assignment for treatment os Chagas Disease</study_design>
            <phase>N/A</phase>
            <hc_freetext>Chagas Disease
Trypanosomiasis
Heart Disease</hc_freetext>
            <i_freetext>Group 1: 750 patients will receive 5 mg/kg per day for 60 days, with an upper limit of dosing at 300 mg per day. There will be a direct relationship between the number of days of treatment and the body weight. Thus, a 60 kg patient will take 300 mg for 60 days, a 80 kg patient with will take 300 mg per day for 80 days and a 40 kg patient will take 300 mg per day for 40 days.
Group 2: placebo</i_freetext>            
        </main>
        <contacts>
        
            <contact>
                <type>public</type>
                <firstname>John</firstname>
                <middlename>Henry</middlename>
                <lastname>Doe</lastname>
                <address>K Street 456 </address>
                <city>Oakland</city>
                <country1>United States</country1>
                <zip>345678</zip>
                <telephone>21-23409985</telephone>
                <email>jhdoe@aol.com</email>
                <affiliation>National Diabetes Association</affiliation>
            </contact>
        
        
            <contact>
                <type>scientific</type>
                <firstname>Candace</firstname>
                <middlename></middlename>
                <lastname>Elek</lastname>
                <address>3200 Lakeside Dr.</address>
                <city>Santa Clara</city>
                <country1>United States</country1>
                <zip>Ca. 950504</zip>
                <telephone>+1 408-845-3133</telephone>
                <email>Candace.Elek@av.abbott.com</email>
                <affiliation>Abbott Vascular</affiliation>
            </contact>
        
        </contacts>
        <countries>
        
            <country2>Brazil</country2>
        
        </countries>
        <criteria>
            <inclusion_criteria>Consenting patients (between 18 and 75 years of age) with serological evidence of Chagas infection (any combination of 2 positive tests) and that have one or more of the following:
Abnormal electrocardiogram with at least two components (complete RBBB or LBBB; left anterior or posterior fascicular block; ventricular premature beat; first degree atrioventricular [AV] block; Mobitz type I AV block; sinus bradycardia; primary ST-T changes; abnormal Q waves; low voltage QRS; or atrial fibrillation);
Abnormal ECG (Mobitz type II, advanced or third degree AV block)</inclusion_criteria>
            <agemin>20Y</agemin>
            <agemax>60Y</agemax>
            <gender>M</gender>
            <exclusion_criteria>NYHA heart failure class IV or decompensated heart failure
Evidence of concomitant coronary artery disease (CAD) or other etiology of dilated cardiomyopathy
Previous treatment with antitrypanosomal agents or an accepted indication for antiparasitic therapy
History of severe alcohol abuse within 2 years
Known chronic renal or hepatic insufficiency
Pregnancy or breast feeding
</exclusion_criteria>
        </criteria>
        <health_condition_code>
            
            <hc_code>C22</hc_code>
            
        </health_condition_code>
        <health_condition_keyword>
            
            <hc_keyword>B01.050.050.199</hc_keyword>
            
        </health_condition_keyword>
        <intervention_code>
            
            <i_code>device</i_code>
            
            <i_code>biological/vaccine</i_code>
            
            <i_code>drug</i_code>
            
        </intervention_code>
        <intervention_keyword>
            
            <i_keyword>B01.050.050.300</i_keyword>
            
        </intervention_keyword>
        <primary_outcome>
            
            <prim_outcome>The first occurrence of any of the following clinically significant outcomes: 
death
cardiac arrest, requiring defibrillator or cardioversion
documented sustained ventricular tachycardia requiring cardioversion
new development of symptomatic congestive heart failure
#pacemaker or implantable cardiac defibrillator implantation
stroke or any other thromboembolic event in patients with no prior thromboembolic phenomena</prim_outcome>
            
        </primary_outcome>
        <secondary_outcome>
            
            <sec_outcome>New development of any of the following echo changes clinically indicated or done for the trial: 
ventricular aneurysm
reduction in left ventricular (LV) ejection fraction &gt; 5%
increase in left ventricular diastolic dysfunction (LVDD) &gt; 5.0 mm compared with baseline
Progression of New York Heart Association (NYHA) functional class by at least one category
Evaluation of safety (adverse events: dermatitis, peripheral neuropathy, gastro-intestinal intolerance, leucopenia [2500 x 10^9 L]), tolerance and adherence to treatment</sec_outcome>
            
        </secondary_outcome>
        <secondary_sponsor>
            
            <sponsor_name></sponsor_name>
            
        </secondary_sponsor>
        <secondary_ids>
            
            <secondary_id>
                <sec_id>U1111-1111-4101</sec_id>
                <issuing_authority>WHO/ICTRP</issuing_authority>    
            </secondary_id>
            
        </secondary_ids>
        <source_support>
            
            <source_name>ACME</source_name>
            
        </source_support>        
    </trial>
</trials>


